Scott R Plotkin

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. pmc Bevacizumab treatment for meningiomas in NF2: a retrospective analysis of 15 patients
    Fabio P Nunes
    Neurology Department, Massachusetts General Hospital, Boston, Massachusetts, United States of America
    PLoS ONE 8:e59941. 2013
  2. ncbi request reprint Update from the 2011 International Schwannomatosis Workshop: From genetics to diagnostic criteria
    Scott R Plotkin
    Department of Neurology and Cancer Center, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Am J Med Genet A 161:405-16. 2013
  3. pmc Quantitative assessment of whole-body tumor burden in adult patients with neurofibromatosis
    Scott R Plotkin
    Department of Neurology and Cancer Center, Massachusetts General Hospital, Boston, Massachusetts, United States of America
    PLoS ONE 7:e35711. 2012
  4. doi request reprint Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients
    Scott R Plotkin
    Department of Neurology and Cancer Center, Massachusetts General Hospital, Boston 02114, USA
    Otol Neurotol 33:1046-52. 2012
  5. pmc Genomic profiling distinguishes familial multiple and sporadic multiple meningiomas
    Yiping Shen
    Molecular Neurogenetics Unit, Center for Human Genetic Research, Massachusetts General Hospital, Boston, MA, 02114, USA
    BMC Med Genomics 2:42. 2009
  6. doi request reprint Hearing improvement after bevacizumab in patients with neurofibromatosis type 2
    Scott R Plotkin
    Department of Neurology, Massachusetts General Hospital, Boston, MA 02114, USA
    N Engl J Med 361:358-67. 2009
  7. doi request reprint Audiologic and radiographic response of NF2-related vestibular schwannoma to erlotinib therapy
    Scott R Plotkin
    Department of Neurology, Massachusetts General Hospital, 55 Fruit Street, Yawkey 9E, Boston, MA 02114, USA
    Nat Clin Pract Oncol 5:487-91. 2008
  8. ncbi request reprint Brain metastases
    April F Eichler
    Scott R Plotkin, MD, PhD Department of Neurology, Stephen E and Catherine Pappas Center for Neuro Oncology, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, Yawkey 9E, Boston, MA 02114, USA
    Curr Treat Options Neurol 10:308-14. 2008
  9. ncbi request reprint Erlotinib for progressive vestibular schwannoma in neurofibromatosis 2 patients
    Scott R Plotkin
    Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts 02114, U S A
    Otol Neurotol 31:1135-43. 2010
  10. ncbi request reprint Update on primary central nervous system lymphoma
    Scott R Plotkin
    Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    Curr Opin Neurol 18:645-53. 2005

Detail Information

Publications55

  1. pmc Bevacizumab treatment for meningiomas in NF2: a retrospective analysis of 15 patients
    Fabio P Nunes
    Neurology Department, Massachusetts General Hospital, Boston, Massachusetts, United States of America
    PLoS ONE 8:e59941. 2013
    ..Our results suggest that a minority of NF2-associated meningiomas shrink during bevacizumab therapy and that these responses were of short duration. These results are comparable to previous studies of bevacizumab in sporadic meningiomas...
  2. ncbi request reprint Update from the 2011 International Schwannomatosis Workshop: From genetics to diagnostic criteria
    Scott R Plotkin
    Department of Neurology and Cancer Center, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Am J Med Genet A 161:405-16. 2013
    ..In the next 5 years, the authors expect that advances in basic research in the pathogenesis of schwannomatosis will lead toward clinical investigations of potential drug therapies...
  3. pmc Quantitative assessment of whole-body tumor burden in adult patients with neurofibromatosis
    Scott R Plotkin
    Department of Neurology and Cancer Center, Massachusetts General Hospital, Boston, Massachusetts, United States of America
    PLoS ONE 7:e35711. 2012
    ..The aim of this study was to establish an international cohort of patients with quantified whole-body internal tumor burden and to correlate tumor burden with clinical features of disease...
  4. doi request reprint Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients
    Scott R Plotkin
    Department of Neurology and Cancer Center, Massachusetts General Hospital, Boston 02114, USA
    Otol Neurotol 33:1046-52. 2012
    ..The aim of this study was to report extended follow-up in a larger cohort of similarly treated patients...
  5. pmc Genomic profiling distinguishes familial multiple and sporadic multiple meningiomas
    Yiping Shen
    Molecular Neurogenetics Unit, Center for Human Genetic Research, Massachusetts General Hospital, Boston, MA, 02114, USA
    BMC Med Genomics 2:42. 2009
    ....
  6. doi request reprint Hearing improvement after bevacizumab in patients with neurofibromatosis type 2
    Scott R Plotkin
    Department of Neurology, Massachusetts General Hospital, Boston, MA 02114, USA
    N Engl J Med 361:358-67. 2009
    ..There is no medical treatment for such tumors...
  7. doi request reprint Audiologic and radiographic response of NF2-related vestibular schwannoma to erlotinib therapy
    Scott R Plotkin
    Department of Neurology, Massachusetts General Hospital, 55 Fruit Street, Yawkey 9E, Boston, MA 02114, USA
    Nat Clin Pract Oncol 5:487-91. 2008
    ..A 48-year-old man presented to a neurologist with complaints of bilateral hearing loss and tinnitus. The patient was a member of a large family affected by neurofibromatosis type 2 and first noted hearing loss 10 years before presentation...
  8. ncbi request reprint Brain metastases
    April F Eichler
    Scott R Plotkin, MD, PhD Department of Neurology, Stephen E and Catherine Pappas Center for Neuro Oncology, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, Yawkey 9E, Boston, MA 02114, USA
    Curr Treat Options Neurol 10:308-14. 2008
    ....
  9. ncbi request reprint Erlotinib for progressive vestibular schwannoma in neurofibromatosis 2 patients
    Scott R Plotkin
    Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts 02114, U S A
    Otol Neurotol 31:1135-43. 2010
    ..We sought to determine the activity of erlotinib for progressive vestibular schwannoma (VS) associated with neurofibromatosis 2 (NF2)...
  10. ncbi request reprint Update on primary central nervous system lymphoma
    Scott R Plotkin
    Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    Curr Opin Neurol 18:645-53. 2005
    ..Numerous studies examining this disorder have been published in the past 2 years. This review will discuss recent advances in the understanding of the pathology, radiographic appearance, and treatment of this disorder...
  11. ncbi request reprint Facial numbness in a man with inguinal and retroperitoneal masses
    Scott R Plotkin
    Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    Nat Clin Pract Oncol 2:54-8; quiz 1 p following 58. 2005
    ..Neurologic examination was significant for diminished sensation over the left face to pinprick, left-sided dysmetria, and mild lateral instability of the trunk while walking...
  12. ncbi request reprint Treatment of relapsed central nervous system lymphoma with high-dose methotrexate
    Scott R Plotkin
    Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Clin Cancer Res 10:5643-6. 2004
    ..The optimal management of these patients has not been determined. We performed a multicenter, retrospective study of high-dose methotrexate in patients with relapsed central nervous system lymphoma...
  13. doi request reprint Spinal ependymomas in neurofibromatosis Type 2: a retrospective analysis of 55 patients
    Scott R Plotkin
    Department of Neurology and Cancer Center, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    J Neurosurg Spine 14:543-7. 2011
    ..The aim of this paper was to define the clinical characteristics of spinal ependymomas associated with neurofibromatosis Type 2 (NF2)...
  14. pmc Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation
    Tracy T Batchelor
    Department of Neurology, Department of Radiation Oncology, Department of Radiology, and Department of Pathology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA 02114
    Proc Natl Acad Sci U S A 110:19059-64. 2013
    ..nonresponders early in the course of this expensive and potentially toxic form of therapy, and these results may provide new insight into the selection of glioblastoma patients most likely to benefit from anti-VEGF treatments. ..
  15. doi request reprint Plasma S100β is not a useful biomarker for tumor burden in neurofibromatosis
    Miriam J Smith
    Department of Neurology, Massachusetts General Hospital, Boston, MA, USA
    Clin Biochem 46:698-700. 2013
    ....
  16. doi request reprint Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide
    Elizabeth R Gerstner
    Stephen E and Catherine Pappas Center for Neuro Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, 55 Fruit Street, Yawkey 9E, Boston, MA 02114, USA
    J Neurooncol 103:325-32. 2011
    ..Vatalanib was well tolerated and this study demonstrates the safety of oral small molecule inhibitors in newly diagnosed GBM patients. Blood biomarkers may be useful as pharmacodynamic markers of response to anti-angiogenic therapies...
  17. pmc NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth
    Marianne F James
    Center for Human Genetic Research, Massachusetts General Hospital, Richard B Simches Research Building, 185 Cambridge St, Boston, MA 02114, USA
    Mol Cell Biol 29:4250-61. 2009
    ....
  18. doi request reprint Anti-vascular endothelial growth factor therapies as a novel therapeutic approach to treating neurofibromatosis-related tumors
    Hon Kit Wong
    Department of Radiation Oncology, Steele Laboratory, Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA
    Cancer Res 70:3483-93. 2010
    ..This study shows that anti-VEGF therapy normalizes the vasculature of schwannoma xenografts in nude mice and successfully controls the tumor growth, probably by reestablishing a natural balance between VEGF and semaphorin 3 signaling...
  19. ncbi request reprint Suggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular schwannoma
    Scott R Plotkin
    Department of Neurology and Cancer Center, Massachusetts General Hospital, Boston, MA 02114, USA
    J Neurooncol 93:61-77. 2009
    ..We encourage adoption of standardized endpoints early in the development of phase II trials for this population to facilitate comparison of results across trials of different agents...
  20. doi request reprint Neurofibromatosis type 1 and pregnancy complications: a population-based study
    Anna R Terry
    Neurosurgical Service, Massachusetts General Hospital, Boston, MA Electronic address
    Am J Obstet Gynecol 209:46.e1-8. 2013
    ..The objective of the study was to determine whether vascular and other complications are more common in pregnant women with neurofibromatosis type 1 (NF1)...
  21. pmc Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma
    Tracy T Batchelor
    Stephen E and Catherine Pappas Center for Neuro Oncology, Yawkey 9E, Massachusetts General Hospital Cancer Center, 55 Fruit St, Boston, MA 02114, USA
    J Clin Oncol 28:2817-23. 2010
    ..Glioblastoma is an incurable solid tumor characterized by increased expression of vascular endothelial growth factor (VEGF). We performed a phase II study of cediranib in patients with recurrent glioblastoma...
  22. doi request reprint Hearing and facial function outcomes for neurofibromatosis 2 clinical trials
    Scott R Plotkin
    From the Neurology Department and Cancer Center S R P and Neurosurgical Service F G B, Massachusetts General Hospital, Boston, MA Department of Neurology and Neurosurgery S L A H, The Children s Hospital at Westmead, University of Sydney, Australia Department of Neurology and Oncology J O B, John Hopkins Medical Institute, Baltimore, MD University Department of Medical Genetics D G E, St Mary s Hospital, Manchester, UK Department of Neurology R E F, Guy s and St Thomas NHS Foundation Trust and Institute of Psychiatry, King s College London, UK Department of Otolaryngology T A H and Audiology C H, Massachusetts Eye and Ear Infirmary and Harvard Medical School T A H, Boston, MA
    Neurology 81:S25-32. 2013
    ..Although hearing loss and facial weakness have been identified as important functional outcomes for patients with NF2, there is a lack of consensus regarding appropriate endpoints in clinical trials...
  23. pmc Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastoma
    Christine Lu-Emerson
    Department of Neurology, Radiation Oncology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA
    Neuro Oncol 15:1079-87. 2013
    ..These data suggest that tumor-associated macrophages may participate in escape from antiangiogenic therapy and may represent a potential biomarker of resistance and a potential therapeutic target in recurrent glioblastoma. ..
  24. doi request reprint Three-dimensional volumetrics for tracking vestibular schwannoma growth in neurofibromatosis type II
    Gordon J Harris
    3D Imaging Service, Department of Radiology, Massachusetts General Hospital, Boston, Massachusetts, USA
    Neurosurgery 62:1314-9; discussion 1319-20. 2008
    ..The current study evaluated the relative sensitivity of volumetric versus linear diameter measurement for assessing VS growth rate and progression...
  25. ncbi request reprint Relationship between whole-body tumor burden, clinical phenotype, and quality of life in patients with neurofibromatosis
    Vanessa L Merker
    Department of Neurology and Cancer Center, Massachusetts General Hospital, Boston, Massachusetts
    Am J Med Genet A 164:1431-7. 2014
    ..2014 Wiley Periodicals, Inc. ..
  26. pmc Clinical features of schwannomatosis: a retrospective analysis of 87 patients
    Vanessa L Merker
    Pappas Center for Neuro Oncology, Yawkey 9E, Massachusetts General Hospital, 55 Fruit Street, Boston, Massachusetts 02114, USA
    Oncologist 17:1317-22. 2012
    ..As more cases are identified, the reported phenotype continues to expand and evolve. We describe the spectrum of clinical findings in a cohort of patients meeting established criteria for schwannomatosis...
  27. pmc Phase 2 study of dose-intense temozolomide in recurrent glioblastoma
    Andrew D Norden
    Center for Neuro Oncology, Dana Farber Brigham and Women s Cancer Center, 450 Brookline Ave, Boston, MA 02215, USA
    Neuro Oncol 15:930-5. 2013
    ..Resistance to temozolomide is partially mediated by O(6)-methylguanine-DNA methyltransferase (MGMT). Because MGMT may be depleted by prolonged temozolomide administration, dose-intense schedules may overcome resistance...
  28. doi request reprint Quality of life among adult patients with neurofibromatosis 1, neurofibromatosis 2 and schwannomatosis: a systematic review of the literature
    Ana Maria Vranceanu
    Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    J Neurooncol 114:257-62. 2013
    ..Mind body interventions that address these domains may provide comprehensive and efficacious long term treatment. ..
  29. pmc Expression of SMARCB1 (INI1) mutations in familial schwannomatosis
    Miriam J Smith
    Department of Neurology, Massachusetts General Hospital, Boston, MA 02114, USA
    Hum Mol Genet 21:5239-45. 2012
    ....
  30. doi request reprint Emotional functioning of patients with neurofibromatosis tumor suppressor syndrome
    Daphne L Wang
    Department of Neurology and Cancer Center, Massachusetts General Hospital Harvard Medical School, Boston, Massachusetts, USA
    Genet Med 14:977-82. 2012
    ..g., hearing loss; pain), little research has examined emotional correlates of neurofibromatosis. The purpose of this study was to examine emotional functioning among adult patients with neurofibromatosis...
  31. doi request reprint Tumor burden in patients with neurofibromatosis types 1 and 2 and schwannomatosis: determination on whole-body MR images
    Wenli Cai
    Department of Radiology, Massachusetts General Hospital, 25 New Chardon St, 400C, Boston, MA 02114, USA
    Radiology 250:665-73. 2009
    ....
  32. pmc Glioblastoma recurrence after cediranib therapy in patients: lack of "rebound" revascularization as mode of escape
    Emmanuelle di Tomaso
    Department of Radiation Oncology, Massachusetts General Hospital and Massachusetts Institute of Technology, Boston, Massachusetts 02114, USA
    Cancer Res 71:19-28. 2011
    ....
  33. ncbi request reprint Anatomic and metabolic evaluation of peripheral nerve sheath tumors in patients with neurofibromatosis 1 using whole-body MRI and (18)F-FDG PET fusion
    Trinity Urban
    From the Department of Radiology, Department of Neurology and Cancer Center, Biostatistics Center, Massachusetts General Hospital, Boston, MA and Corades, S L, Madrid, Spain
    Clin Nucl Med 39:e301-7. 2014
    ..The objective of this study was to identify clinical and MRI-derived variables that predicted increased metabolic activity of neurofibromas in NF1 patients as determined by PET...
  34. doi request reprint Recommendations for imaging tumor response in neurofibromatosis clinical trials
    Eva Dombi
    From the Pediatric Oncology Branch E D, B C W, National Cancer Institute, Bethesda, MD Department of Neurology S L A H, The Children s Hospital at Westmead, Sydney, Australia Department of Medical Genetics D B V, Mayo Clinic, Rochester, MN Neurosurgical Service F G B, Department of Radiology G J H, and Department of Neurology and Cancer Center S R P, Massachusetts General Hospital, Boston, MA Department of Neuroradiology S C, King s College Hospital, London, UK Department of Genetic Medicine D G E, MAHSC, St Mary s Hospital, Manchester, UK Division of Oncology M J F and Department of Radiology D J, The Children s Hospital of Philadelphia Department of Pediatrics M J F, The Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA Department of Neurosurgery S G, Hopital Beaujon, Clichy, France Division of Pediatric Hematology Oncology and NYU Cancer Institute M A K, NYU Langone Medical Center, New York, NY Department of Genetics B R K, University of Alabama at Birmingham, Birmingham, AL Department of Neurology V M, University Medical Center Hamburg Eppendorf, Hamburg, Germany Department of Radiology T Y P, Boston Children s Hospital
    Neurology 81:S33-40. 2013
    ....
  35. doi request reprint Whole-body MRI in neurofibromatosis: incidental findings and prevalence of scoliosis
    Jacob L Jaremko
    Musculoskeletal Imaging and Intervention, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, 55 Fruit Street, Boston, MA 02114, USA
    Skeletal Radiol 41:917-23. 2012
    ..To demonstrate incidental findings and scoliosis on whole-body MRI (WBMRI) in patients with neurofibromatosis type 1 and 2 (NF1 & NF2, respectively), and schwannomatosis...
  36. ncbi request reprint The neurofibromatoses. Part 2: NF2 and schwannomatosis
    Christine Lu-Emerson
    Department of Neurology, University of Washington, Seattle, WA, USA
    Rev Neurol Dis 6:E81-6. 2009
    ..Recently, germline alterations in the SMARCB1/INI1 gene have been implicated in both familial and sporadic forms of this disorder. Neurologists play an important role in the diagnosis and management of the neurofibromatoses...
  37. pmc Outcomes of hospitalization in pregnant women with CNS neoplasms: a population-based study
    Anna R Terry
    Neurosurgical Service, White 502, Massachusetts General Hospital, Boston, MA 02114, USA
    Neuro Oncol 14:768-76. 2012
    ..Additional research is needed to improve understanding of obstetric risk in these patients and to assist with treatment, counseling, and monitoring during delivery...
  38. ncbi request reprint Genetic causes of brain tumors: neurofibromatosis, tuberous sclerosis, von Hippel-Lindau, and other syndromes
    Christopher J Farrell
    Department of Neurosurgery, White 502, Massachusetts General Hospital and Harvard Medical School, 55 Fruit Street, Boston, MA 02114, USA
    Neurol Clin 25:925-46, viii. 2007
    ....
  39. pmc Modeling NF2 with human arachnoidal and meningioma cell culture systems: NF2 silencing reflects the benign character of tumor growth
    Marianne F James
    Molecular Neurogenetics Unit, Center for Human Genetic Research, Massachusetts General Hospital, Richard B Simches Research Building, 185 Cambridge Street, Boston, MA 02114, USA
    Neurobiol Dis 29:278-92. 2008
    ..Merlin suppression by RNAi in arachnoidal cells replicated merlin-deficient meningioma features, thus establishing these cell systems as disease-relevant models for studying NF2 tumorigenesis...
  40. doi request reprint Achieving consensus for clinical trials: the REiNS International Collaboration
    Scott R Plotkin
    From the Neurology Department and Cancer Center S R P, Massachusetts General Hospital, Boston, MA Department of Neurology, Neurosurgery, and Oncology J O B, Johns Hopkins, Baltimore, MD Pediatric Oncology Branch E D, P L W, B C W, National Cancer Institute, Bethesda, MD Division of Oncology, Department of Pediatrics M J F, The Children s Hospital of Pennsylvania, Philadelphia Plymouth University Peninsula Schools of Medicine and Dentistry C O H, Plymouth, United Kingdom and The Jennifer and Daniel Gilbert Neurofibromatosis Institute K S W, Children s National Medical Center, Washington, DC
    Neurology 81:S1-5. 2013
    ..Ultimately, we plan to engage industry partners and national regulatory agencies in this process to facilitate the approval of drugs for patients with NF...
  41. doi request reprint Natural history of vestibular schwannoma growth and hearing decline in newly diagnosed neurofibromatosis type 2 patients
    Scott R Plotkin
    Department of Neurology and Cancer Center, Biostatistics Center, and Neurosurgical Service, Massachusetts General Hospital, Boston, Massachusetts and Neurotology, House Clinic, Los Angeles, California, U S A
    Otol Neurotol 35:e50-6. 2014
    ..To determine the rate of growth in vestibular schwannomas and the rate of hearing decline in neurofibromatosis type 2 (NF2) patients not undergoing active treatment..
  42. doi request reprint Understanding relationships between autism, intelligence, and epilepsy: a cross-disorder approach
    Agnies M van Eeghen
    Department of Neurology, The Carol and James Herscot Center for Tuberous Sclerosis Complex, Massachusetts General Hospital, Boston, MA, USA
    Dev Med Child Neurol 55:146-53. 2013
    ....
  43. doi request reprint Role of resection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis type 1
    Gavin P Dunn
    Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
    J Neurosurg 118:142-8. 2013
    ..Here, the authors aim to examine what role the extent of resection and other covariates play in the long-term survival of patients with NF1 in the setting of MPNST...
  44. ncbi request reprint Value of PET in the assessment of patients with neurofibromatosis type 1
    Miriam A Bredella
    Department of Radiology, Massachusetts General Hospital, 55 Fruit St, Yawkey 6E, Boston, MA 02114, USA
    AJR Am J Roentgenol 189:928-35. 2007
    ..The objective of our study was to investigate the use of PET in the detection of malignant peripheral nerve sheath tumors (MPNSTs) in patients with neurofibromatosis type 1 (NF1)...
  45. doi request reprint Neurofibromatoses
    Erik J Uhlmann
    Massachusetts General Hospital, Boston, MA, USA
    Adv Exp Med Biol 724:266-77. 2012
    ..In this chapter, the genetics, molecular mechanism of disease, as well as clinical features, diagnosis and treatment are discussed...
  46. ncbi request reprint Primary nervous system lymphoma
    Scott R Plotkin
    Brain Tumor Center, Cox 315, Massachusetts General Hospital, 100 Blossom Street, Boston, MA 02114, USA
    Curr Treat Options Oncol 3:525-35. 2002
    ..Given the rarity of this tumor, patients with PNSL should be referred to tertiary cancer centers where ongoing clinical trials are underway to identify the optimal treatment of PNSL...
  47. ncbi request reprint Turner syndrome and meningioma: Support for a possible increased risk of neoplasia in Turner syndrome
    Danielle B Pier
    Medical Genetics Unit, MassGeneral Hospital for Children, Boston, MA, USA
    Eur J Med Genet 57:269-74. 2014
    ..We are not able to prove causation between these two entities, but suggest that neoplasia may be a rare associated medical problem in Turner syndrome. Additional case reports and extension of population-based studies are needed. ..
  48. ncbi request reprint Long-term toxicity of bevacizumab therapy in neurofibromatosis 2 patients
    Katherine M Slusarz
    Center for Neurofibromatosis and Allied Disorders, Center for Human Genetic Research, Massachusetts General Hospital, Boston, MA, USA
    Cancer Chemother Pharmacol 73:1197-204. 2014
    ..Hypertension and proteinuria are common side effects of treatment. However, the long-term toxicity of bevacizumab in this population has not been reported...
  49. doi request reprint Chemotherapy: present and future
    Anna R Terry
    Department of Neurosurgery, Massachusetts General Hospital, White 502, 55 Fruit Street, Boston, MA 02114, USA
    Otolaryngol Clin North Am 45:471-86, x. 2012
    ..The article also defines and recommends the use of specific clinical end points in future drug trials, describes previous and current experience with anti-VEGF and anti-EGFR agents, and delineates areas of future research...
  50. ncbi request reprint The Neurofibromatoses. Part 1: NF1
    Christine Lu-Emerson
    Department of Neurology, University of Washington, Seattle, WA, USA
    Rev Neurol Dis 6:E47-53. 2009
    ..Current treatment of patients with NF1 remains primarily surgical. Genetic counseling is essential for adult patients because molecular diagnostic testing can minimize the risk of transmission to children...
  51. pmc Use of video to facilitate end-of-life discussions with patients with cancer: a randomized controlled trial
    Areej El-Jawahri
    Departments of Medicine, Neurology and Cancer Center, and Oncology, Massachusetts General Hospital, 50 Staniford St, 9th Floor, Boston, MA 02114, USA
    J Clin Oncol 28:305-10. 2010
    ..To determine whether the use of a goals-of-care video to supplement a verbal description can improve end-of-life decision making for patients with cancer...
  52. ncbi request reprint Ramsay Hunt syndrome in a patient with metastatic lung cancer to brain
    Roy N Alcalay
    Department of Neurology, Massachusetts General Hospital, Boston, MA, 02114, USA
    J Neurooncol 86:55-6. 2008
  53. doi request reprint Facial reanimation of patients with neurofibromatosis type 2
    Kalpesh T Vakharia
    Department of Otology and Laryngology, Division of Facial Plastic and Reconstructive Surgery, Massachusetts Eye and Ear Infirmary and Harvard Medical School, Boston, Massachusetts 02114, USA
    Neurosurgery 70:237-43. 2012
    ..Historically, physicians have not attempted to treat facial paralysis in these patients...
  54. ncbi request reprint Clinical reasoning: a case of multiple intracerebral hemorrhages
    Linda C Wendell
    Department of Neurology, Rhode Island Hospital Brown University, Providence, RI, USA
    Neurology 69:E30-4. 2007
  55. ncbi request reprint Peripheral and cranial nerve sheath tumors
    Maciej M Mrugala
    Stephen E and Catherine Pappas Center for Neuro Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA
    Curr Opin Neurol 18:604-10. 2005
    ..Vestibular schwannomas, neurogenetic syndromes such as schwannomatosis and multiple isolated neurofibromas, and malignant peripheral nerve sheath tumors are covered in this review...